ICI-190,622

ICI-190,622.svg

{{Infobox drug | IUPAC_name = (2S)-N-[(2S)-1-[(2S)-2-[[2-(2,6-dichlorophenyl)acetyl]amino]-3-methylbutanoyl]pyrrolidin-2-yl]-2-[(2S)-2-[[2-(2,6-dichlorophenyl)acetyl]amino]-3-methylbutanoyl]pyrrolidine-1-carboxamide | image = | width = | alt = | caption = | tradename = | synonyms = | CAS_number = | ATC_prefix = | ATC_suffix = | PubChem = | DrugBank = | ChemSpiderID = | UNII = | KEGG = | ChEBI = | ChEMBL = | IUPHAR_ligand = | C = | H = | N = | O = | molecular_weight = | bioavailability = | protein_bound = | metabolism = | elimination_half-life = | excretion = | pregnancy_AU = | pregnancy_US = | pregnancy_category = | legal_AU = | legal_BR = | legal_CA = | legal_DE = | legal_UK = | legal_US = | legal_status = | routes_of_administration = }}

ICI-190,622 is an experimental drug that has been studied for its potential therapeutic effects. It is a synthetic compound that has been investigated primarily for its pharmacological properties and potential applications in medicine.

Pharmacology

ICI-190,622 is known to interact with specific receptors in the body, influencing various biochemical pathways. The exact mechanism of action is still under investigation, but it is believed to modulate the activity of certain neurotransmitters.

Potential Applications

Research on ICI-190,622 has focused on its potential use in treating various medical conditions. Preliminary studies suggest that it may have applications in the treatment of neurological disorders, psychiatric disorders, and other conditions that involve neurotransmitter dysregulation.

Clinical Trials

As of now, ICI-190,622 is in the experimental stages, and clinical trials are ongoing to determine its safety and efficacy. These trials are crucial for understanding the potential benefits and risks associated with the drug.

Side Effects

The side effects of ICI-190,622 are not fully known due to its experimental status. However, like all drugs, it may cause adverse reactions in some individuals. Ongoing research aims to identify and mitigate these potential side effects.

Regulatory Status

ICI-190,622 has not yet been approved by any major regulatory agency such as the Food and Drug Administration (FDA) or the European Medicines Agency (EMA). It remains an investigational drug under study.

See Also

• Pharmacology
• Neurotransmitter
• Clinical trial
• Neurological disorder
• Psychiatric disorder

References

‎

---

Translate: - East Asian 中文, 日本, 한국어, South Asian हिन्दी, தமிழ், తెలుగు, Urdu, ಕನ್ನಡ, Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, বাংলা
European español, Deutsch, français, Greek, português do Brasil, polski, română, русский, Nederlands, norsk, svenska, suomi, Italian
Middle Eastern & African عربى, Turkish, Persian, Hebrew, Afrikaans, isiZulu, Kiswahili,
Other Bulgarian, Hungarian, Czech, Swedish, മലയാളം, मराठी, ਪੰਜਾਬੀ, ગુજરાતી, Portuguese, Ukrainian